Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Wright, Heathcote R; Keeffe, Jill; Taylor, Hugh R.

doi:10.1136/bjo.2006.095562

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are potential biases inherent in the methodology of uncontrolled cohort studies. Unfortunately, there have been no randomised controlled trials (RCT) to conclusively prove the benefit of mass antibiotic distribution 41 . Monitoring for the emergence of resistant organisms and to confirm the effectiveness of programs is vital to maintain public confidence in the safety and efficacy of such a global campaign.…”

Section: Antibioticsmentioning

confidence: 99%

Trachoma and poverty: unnecessary blindness further disadvantages the poorest people in the poorest countries

Wright

Turner

Taylor

2007

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Trachoma is the leading cause of infectious blindness worldwide. Many populations living in poverty are affected by trachoma. The infectious organism is provided with an ideal milieu for transmission, where markers of poverty are present. These include overcrowding, lack of adequate water resources, limited use of water for personal hygiene, inadequate waste disposal and other conditions that encourage the proliferation of flies. This review summarises treatment strategies that have been effectively instituted in many countries to reduce the prevalence of trachoma. The review promotes partnerships working towards achieving the Millennium Development Goals developed by the United Nations to address issues associated with poverty. These goals are in keeping with many of the strategies to reduce the burden of potentially blinding trachoma that afflicts some of the world's poorest citizens.

show abstract

Section: Antibioticsmentioning

confidence: 99%

Trachoma and poverty: unnecessary blindness further disadvantages the poorest people in the poorest countries

Wright

Turner

Taylor

2007

Clinical and Experimental Optometry

View full text Add to dashboard Cite

show abstract

“…Some argue that the benefits of azithromycin treatment have been demonstrated so convincingly that use of a placebo arm in a trial would be unethical. 9 This argument is questionable; it is very unlikely that delaying treatment of active trachoma or C trachomatis by 6 months to a year will increase the risk of blindness from trachoma in the decades to come, and we still do not know enough about the possible harmful effects of treatment. We also know that prevalence of trachoma can dramatically decline even without any specific intervention.…”

Section: Trial Designmentioning

confidence: 99%

Topical azithromycin: new evidence?

Kuper¹,

Wormald²

2007

British Journal of Ophthalmology

View full text Add to dashboard Cite

Anterior lamellar repositioning with complete lid split: a modified method for treating upper eyelids trichiasis in Asian patients

Yang

Zhou

et al. 2009

Journal of Plastic, Reconstructive & Aesthetic Surgery

View full text Add to dashboard Cite

Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Cited by 6 publications

References 16 publications

Trachoma and poverty: unnecessary blindness further disadvantages the poorest people in the poorest countries

Trachoma and poverty: unnecessary blindness further disadvantages the poorest people in the poorest countries

Topical azithromycin: new evidence?

Anterior lamellar repositioning with complete lid split: a modified method for treating upper eyelids trichiasis in Asian patients

Contact Info

Product

Resources

About